Background and Aims <p>Activation of hepatic stellate cells (HSCs) and subsequent dysregulation of the TGF-β1 signaling pathway are central to the progression of hepatic fibrosis. Neuropilin-1 (NRP1) has been identified as a co-receptor involved in multiple signaling pathways, yet its role in modulating TGF-β receptor stability in HSCs remains to be fully elucidated. This study investigated the regulatory role of the NRP1/Src/Rab7 axis in TβRI lysosomal degradation during HSC activation.</p> Methods <p>Hepatic fibrosis was induced in male C57BL/6 mice via intraperitoneal CCl<sub>4</sub> injection for four weeks. HSC-specific knockdown of <i>Nrp1</i> was achieved using an AAV8-pLrat-sh<i>Nrp1</i> vector. TβRI stability and lysosomal degradation were evaluated through cycloheximide (CHX) chase assays and chloroquine treatment. The impact on the TGF-β1/Smad signaling pathway was assessed both in vitro and in vivo.</p> Results <p><i>Nrp1</i> silencing in primary HSCs reduced TβRI protein levels and attenuated p-Smad2/3 signaling without affecting mRNA levels. Consistently, NRP1 deficiency accelerated lysosomal degradation of TβRI, accompanied by increased TβRI–LAMP1 colocalization and enhanced trafficking of TβRI into Rab7-positive late endosomes. Mechanistically, NRP1 loss diminished Src kinase activity and consequently reduced Src-dependent tyrosine phosphorylation of Rab7, leading to elevated Rab7-GTP levels and enhanced late endosomal sorting of TβRI. <i>Rab7</i> knockdown or Src reactivation partially rescued TβRI stability and restored downstream signaling. In vivo, HSC-specific <i>Nrp1</i> knockdown attenuated CCl<sub>4</sub>-induced fibrosis and reduced TβRI levels, while Rab7 inhibition partially reversed these effects.</p> Conclusions <p>These data suggest that the NRP1/Src/Rab7 axis contributes to TβRI stability by modulating its lysosomal degradation pathway. Targeting this axis may provide a potential approach for intervening in the progression of hepatic fibrosis.</p> <p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

NRP1 promotes hepatic fibrosis by regulating Src/Rab7-mediated lysosomal degradation of TβRI

  • Zhe Jia,
  • Xiaodong Song,
  • Jie Bai

摘要

Background and Aims

Activation of hepatic stellate cells (HSCs) and subsequent dysregulation of the TGF-β1 signaling pathway are central to the progression of hepatic fibrosis. Neuropilin-1 (NRP1) has been identified as a co-receptor involved in multiple signaling pathways, yet its role in modulating TGF-β receptor stability in HSCs remains to be fully elucidated. This study investigated the regulatory role of the NRP1/Src/Rab7 axis in TβRI lysosomal degradation during HSC activation.

Methods

Hepatic fibrosis was induced in male C57BL/6 mice via intraperitoneal CCl4 injection for four weeks. HSC-specific knockdown of Nrp1 was achieved using an AAV8-pLrat-shNrp1 vector. TβRI stability and lysosomal degradation were evaluated through cycloheximide (CHX) chase assays and chloroquine treatment. The impact on the TGF-β1/Smad signaling pathway was assessed both in vitro and in vivo.

Results

Nrp1 silencing in primary HSCs reduced TβRI protein levels and attenuated p-Smad2/3 signaling without affecting mRNA levels. Consistently, NRP1 deficiency accelerated lysosomal degradation of TβRI, accompanied by increased TβRI–LAMP1 colocalization and enhanced trafficking of TβRI into Rab7-positive late endosomes. Mechanistically, NRP1 loss diminished Src kinase activity and consequently reduced Src-dependent tyrosine phosphorylation of Rab7, leading to elevated Rab7-GTP levels and enhanced late endosomal sorting of TβRI. Rab7 knockdown or Src reactivation partially rescued TβRI stability and restored downstream signaling. In vivo, HSC-specific Nrp1 knockdown attenuated CCl4-induced fibrosis and reduced TβRI levels, while Rab7 inhibition partially reversed these effects.

Conclusions

These data suggest that the NRP1/Src/Rab7 axis contributes to TβRI stability by modulating its lysosomal degradation pathway. Targeting this axis may provide a potential approach for intervening in the progression of hepatic fibrosis.